( NASDAQ-SMALL:BDSI )

News from BioDelivery Sciences International, Inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Nov 27, 2017, 07:00 ET BioDelivery Sciences Announces Ohio Workers Compensation Adding BELBUCA and BUNAVAIL to Formulary

BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that the Ohio Bureau of Workers Compensation (BWC) has approved a change to its...


Nov 16, 2017, 07:00 ET BioDelivery Sciences to Present at the 29th Annual Piper Jaffray Conference

BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a specialty pharmaceutical company with a focus in pain management and addiction medicine,...


Nov 09, 2017, 16:01 ET BioDelivery Sciences Reports Third Quarter 2017 Financial Results and Provides Corporate Update

BioDelivery Sciences International, Inc. (BDSI) today reported financial results for the three and nine months ended September 30, 2017, and...


Oct 30, 2017, 07:00 ET BioDelivery Sciences to Host Conference Call and Webcast Reporting Third Quarter 2017 Financial Results on November 9

BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that it will report its third quarter 2017 financial results and host a...


Oct 12, 2017, 07:00 ET BioDelivery Sciences Announces Patent Litigation Settlement Agreement with Teva

BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a specialty pharmaceutical company with a focus in pain management and addiction medicine,...


Oct 06, 2017, 07:00 ET BioDelivery Sciences Participates in U.S. Department of Health and Human Services Round Table Discussion on Pain Management and Opioid Dependence

BioDelivery Sciences International, Inc. (NASDAQ: BDSI) participated in a round table meeting convened this week in Washington, D.C. by the U.S....


Sep 19, 2017, 07:00 ET BioDelivery Sciences to Present at the Cantor Fitzgerald Global Healthcare Conference and the Ladenburg Thalmann 2017 Healthcare Conference

BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that Dr. Mark A. Sirgo, Vice Chairman, President and Chief Executive Officer,...


Sep 12, 2017, 08:00 ET BioDelivery Sciences Announces Granting of Market Authorization Transfer by Health Canada for BELBUCA® and Associated Milestone Payment

BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced today that Health Canada has granted market authorization to formally transfer...


Sep 07, 2017, 08:00 ET BioDelivery Sciences Presents Data on BELBUCA® (buprenorphine) Buccal Film at the PAINWeek 2017 Conference

BioDelivery Sciences International, Inc. (NASDAQ: BDSI) presented three posters including results from an analysis of data which evaluated the...


Aug 24, 2017, 07:30 ET BioDelivery Sciences to Present at the Rodman & Renshaw 19th Annual Global Investment Conference

BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that Dr. Mark A. Sirgo, Vice Chairman, President and Chief Executive Officer,...


Aug 23, 2017, 07:30 ET BioDelivery Sciences President and Chief Executive Officer Dr. Mark A. Sirgo to Retire at Year-End While Continuing as Vice Chairman

BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced today that at the end of 2017, Dr. Mark A. Sirgo will retire as BDSI's President...


Aug 17, 2017, 07:00 ET BioDelivery Sciences to Present Three Posters on BELBUCA® and BUNAVAIL® at PAINWeek 2017

BioDelivery Sciences International, Inc. (NASDAQ: BDSI) will present three posters reviewing the potential impacts of BELBUCA® (buprenorphine)...


Aug 09, 2017, 16:01 ET BioDelivery Sciences Reports Second Quarter 2017 Financial Results and Provides Corporate Update

BioDelivery Sciences International, Inc. (BDSI) today reported financial results for the three and six months ended June 30, 2017, and...


Jul 31, 2017, 07:00 ET BioDelivery Sciences Publishes Shareholder Letter with Mid-Year Corporate Update

BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a specialty pharmaceutical company with a focus in pain management and addiction medicine,...


Jul 28, 2017, 09:27 ET BioDelivery Sciences to Host Conference Call and Webcast Reporting Second Quarter 2017 Financial Results on Wednesday, August 9

BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that it will report its second quarter 2017 financial results and host a...


Jul 12, 2017, 07:30 ET BioDelivery Sciences Signs Exclusive Agreement With Purdue Pharma (Canada) For The Licensing And Distribution Rights Of BELBUCA® In Canada

Today, BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a specialty pharmaceutical company with a focus in pain management and addiction...


Jun 23, 2017, 07:00 ET BioDelivery Sciences Announces Health Canada Approval of BELBUCA®

BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that Health Canada, the regulatory authority in Canada, has issued a Notice of...


Jun 21, 2017, 08:48 ET BioDelivery Sciences Announces Agreement with CVS/Caremark for BELBUCA® and BUNAVAIL® Through 2020

BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that it has signed an agreement with CVS/Caremark extending access to both...


Jun 01, 2017, 07:49 ET BioDelivery Sciences to Present at the Jefferies 2017 Healthcare Conference and the William Blair 2017 Growth Stock Conference

BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that Dr. Mark A. Sirgo, President and Chief Executive Officer, will present at...


May 15, 2017, 19:17 ET BioDelivery Sciences Reports First Quarter 2017 Financial Results and Provides Corporate Update

BioDelivery Sciences International, Inc. (BDSI) today reported financial results for the first quarter ended March 31, 2017 and provided a...


May 09, 2017, 09:23 ET BioDelivery Sciences to Host Conference Call and Webcast Reporting First Quarter 2017 Financial Results on Monday, May 15

BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that it will report its first quarter 2017 financial results and host a...


May 02, 2017, 07:00 ET BioDelivery Sciences Announces the Approval of BUNAVAIL® for Induction of Buprenorphine Treatment for Opioid Dependence

BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that the U.S. Food and Drug Administration (FDA) has approved a Supplemental New...


Apr 26, 2017, 07:00 ET BioDelivery Sciences to Present at the Deutsche Bank 42nd Annual Health Care Conference

BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that Dr. Mark A. Sirgo, President and Chief Executive Officer, will present at...


Mar 31, 2017, 07:00 ET BioDelivery Sciences Announces the Granting of Two New Patents to be Listed in FDA's Orange Book Further Extending and Strengthening Patent Protection on BELBUCA®, BUNAVAIL® and ONSOLIS®

BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that two important new patents were granted extending patent protection around...


Mar 17, 2017, 06:30 ET BioDelivery Sciences Provides Corporate Update and Reports Fourth Quarter and Full-Year 2016 Financial Results

BioDelivery Sciences International, Inc. (BDSI) today reported financial results for the fourth quarter and full year ended December 31, 2016, and...